TAS-102 and Irinotecan after Surgery for the Treatment of ctDNA Positive, Stage II-III Colorectal Cancer

Inclusion Criteria

• Patients must have histologically or cytologically confirmed adenocarcinoma of the colon (high rectal cancer is eligible if resected and no radiation needed). Other histologies which are treated per National Comprehensive Cancer Network (NCCN) guidelines for adjuvant colon cancer are eligible
• Must have stage II or stage III colorectal cancer eligible for adjuvant doublet chemotherapy for 6 months
• Must have ctDNA positive assay (tested by Signatera MRD assay) after 3 months of adjuvant chemotherapy
• Age >= 18 years * Because no dosing or adverse event data are currently available on the use of TAS-102 in patients < 18 years of age, children are excluded from this study but will be eligible for future pediatric single-agent trials, if applicable
• Eastern Cooperative Oncology Group (ECOG) performance status =< 2
• Life expectancy of greater than 3 months
• Leukocytes >= 3,000/mcL
• Absolute neutrophil count >= 1,500/mcL
• Platelets >= 80,000/mcl
• Total bilirubin within normal institutional limits
• Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional upper limit of normal or =< 5 x if liver metastases are present
• Creatinine < 1.5 x upper limit of normal (ULN)
• The effects of TAS-102 on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because topoisomerase inhibitors are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: ** Has not undergone a hysterectomy or bilateral oophorectomy; or ** Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
• Ability to swallow tablets
• Ability to understand and the willingness to sign a written informed consent
• Members of all races and ethnic groups are eligible for this trial. Non-English speaking, deaf, hard of hearing and illiterate individuals are eligible for this trial.

Exclusion Criteria

• Patients who have had major surgery within 4 weeks, or chemotherapy or radiotherapy within 2 weeks prior to cycle 1 day 1
• All toxicities attributed to prior anti-cancer therapy other than alopecia must have resolved to grade 1 or baseline
• Patients may not be receiving any other investigational agents
• Patients with known metastases
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to TAS-102, irinotecan or other agents used in study
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Prior treatment with TAS-102 at any time or irinotecan within 90 days from enrollment
• History of another primary cancer within the last 3 years with the exception of non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in-situ
• Inability to comply with study and follow-up procedures as judged by the investigator
• Patients who are pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants